Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ruxolitinib in Combination With Chemotherapy for Untreated Nodal T-Follicular Helper (TFH) Cell Lymphomas

NCT07278856 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07278856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07278856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ruxolitinib in Combination With Chemotherapy for Untreated Nodal T-Follicular Helper (TFH) Cell Lymphomas
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Recruiting
Start date
December 16, 2025
Completion date
March 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

follicular helper t-cell lymphoma, follicular helper t-cell lymphoma, angioimmunoblastic-type, follicular helper t-cell lymphoma, follicular-type, follicular helper t-cell lymphoma, not otherwise specified, mature t-cell and nk-cell non-hodgkin lymphoma, peripheral t-cell lymphoma, not otherwise specified